Biocryst Pharmaceuticals (BCRX) Change in Receivables (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Change in Receivables came in at $474000.0 in Q1 2026, down 96.61% YoY from $14.0 million in Q1 2025, and down 96.94% on a QoQ basis from $15.5 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Change in Receivables (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Change in Receivables data on file, last reported at $474000.0 in Q1 2026.
- Quarterly Change in Receivables fell 96.61% year-over-year to $474000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (down 29.08% YoY) and the FY2025 annual result came in at $36.8 million, up 62.16% from the prior year.
- Change in Receivables slipped to $474000.0 in Q1 2026, from $15.5 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $15.5 million in Q4 2025 to a low of -$3.8 million in Q3 2023.
- A 5-year average of $5.1 million and a median of $5.3 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 2600.38% — and 2023, when it tumbled 358.96%.
- Tracing BCRX's Change in Receivables over 5 years: stood at $7.6 million in 2022, then sank by 61.14% to $3.0 million in 2023, then soared by 145.66% to $7.3 million in 2024, then soared by 112.36% to $15.5 million in 2025, then sank by 96.94% to $474000.0 in 2026.
- The last three Change in Receivables figures came in at $474000.0 (Q1 2026), $15.5 million (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Jun 30, 2026 | 1.49 Mn |
| Mar 31, 2026 | 474,000.00 |
| Mar 31, 2026 | 474,000.00 |
| Dec 31, 2025 | 15.49 Mn |
| Dec 31, 2025 | 15.49 Mn |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 7.31 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 13.99 Mn |
| Mar 31, 2025 | 13.99 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 8.25 Mn |
| Jun 30, 2024 | 8.25 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.84 Mn |